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Background and PurposezzSleep-related falling out of bed (SFOB), with its potential for 
significant injury, has not been a strong focus of investigation in Parkinson’s disease (PD) to date. 
We describe the demographic and clinical characteristics of PD patients with and without SFOB.
MethodszzWe performed a retrospective analysis of 50 consecutive PD patients, who complet-
ed an REM sleep behavior disorder screening questionnaire (RBDSQ), questionnaires to assess 
for RBD clinical mimickers and questions about SFOB and resulting injuries. Determination of 
high risk for RBD was based on an RBDSQ score of 5 or greater.
ResultszzThirteen patients reported history of SFOB (26%). Visual hallucinations, sleep-relat-
ed injury, quetiapine and amantadine use were more common in those patients reporting SFOB. 
Twenty-two patients (44%) fulfilled criteria for high risk for RBD, 12 of which (55%) reported 
SFOB. Five patients reported injuries related to SFOB. SFOB patients had higher RBDSQ scores 
than non-SFOB patients (8.2±3.0 vs. 3.3±2.0, p<0.01). For every one unit increase in RBDSQ 
score, the likelihood of SFOB increased two-fold (OR 2.4, 95% CI 1.3-4.2, p<0.003).
ConclusionszzSFOB may be a clinical marker of RBD in PD and should prompt confirmatory 
polysomnography and pharmacologic treatment to avoid imminent injury. Larger prospective 
studies are needed to identify risk factors for initial and recurrent SFOB in PD.
J Clin Neurol 2012;8:51-57
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Introduction
REM sleep behavior disorder (RBD) is characterized by loss 
of normal skeletal muscle atonia during REM sleep associat-
ed with vivid, and often, aggressive dreaming with patients 
performing dream-enacting behaviors.
1-3 These events are 
non-stereotypical and can range from simple, nonviolent mo-
tions (laughing, jerking) to more forceful, complex manifes-
tations (yelling, punching, jumping from bed). RBD is a well 
recognized cause of sleep-related-injury in Parkinson’s disease 
(PD).
4,5 Sleep-related falling out of bed (SFOB) or “jumping 
out of bed” has been reported in studies of idiopathic RBD 
and sleep-related violence;1,2,6-9 but there is limited information 
about SFOB in PD.
3-5,10,11 SFOB is not exclusively a symptom 
of RBD. It may occur during somnambulism, nocturnal sei-
zures, violent periodic limb movements in sleep, or severe 
sleep disordered breathing (SDB).
8,9,12
RBD is a harbinger of neurodegenerative disease, with about 
50% of patients eventually developing PD, multiple system 
atrophy, or Lewy body dementia approximately a decade from 
RBD onset.
13 It can precede PD, occur simultaneously, or fol-
low the diagnosis of PD.
2,4,8,10,11,14 Prevalence estimates of RBD 
in the general and elderly population is low (0.4-0.5%),
7,15 
whereas in PD, it varies between 15-72%.
4,5,10,14,16-20 Differing 
diagnostic criteria for PD and RBD, and selection bias may 
account for the observed variation in RBD rates in PD.Sleep-Related Falling Out of Bed in PD
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To our knowledge, there is no study to date, describing 
SFOB in PD. Improved understanding of its prevalence in PD 
and predisposing patient characteristics may help improve 
rapid referral for comprehensive sleep medicine consultation 
and immediate institution of injury prevention strategies. In 
this study, we describe the demographic and clinical charac-
teristics of PD patients with and without SFOB. 
Methods
Subjects
We performed a retrospective analysis of 50 consecutive PD 
patients seen at the University of Miami Movement Disorders 
Clinic over a three month period (April-June 2009). PD diag-
nosis was made with clinical criteria according to UK Parkin-
son’s Disease Society Brain Bank.
21 Patients completed an 
assessment and examination by a movement disorders spe-
cialist, an RBD screening questionnaire (RBDSQ), questions 
about history of SFOB and SFOB-related injury and screen-
ing questions for SDB and somnambulism (both clinical mim-
ickers of RBD). All patients had a minimum of two years of 
follow up prior to enrolling visit. Patients were excluded if 
they had a temporal association (within one month) of SFOB 
onset with the introduction of medications, particularly anti-
depressants. When possible, questionnaires were completed 
by the patient and bed partner. The study was approved by the 
University of Miami institutional review board. Informed con-
sent was obtained from all patients participating in this study.
Assessments
On the day of questionnaire completion, the following vari-
ables were collected: age, gender, PD duration, modified 
Hoehn and Yahr (H&Y) stage in the on-state, and medica-
tions. PD duration was calculated from the time the patient 
first reported PD motor symptoms. The levodopa equivalent 
daily dosage (LEDD) was calculated per published criteria.
22 
Medical records were reviewed for the following historical 
details: age of PD onset, history of dyskinesias, hallucina-
tions, and mood/anxiety disorder. Mood or anxiety disorders 
were defined by medication use for these specific indications. 
The records were also reviewed for history of SFOB and re-
lated injuries mentioned during clinical visits.
RBDSQ
As developed by Stiasny-Kolster et al.
23 the RBDSQ is a 10-
item, patient self-rating instrument reflecting the core clinical 
features of RBD as determined by the International Classifi-
cation of Sleep Disorders-Revised Diagnostic and Coding 
Manual.
24 The features of the first nine items are listed in 
Fig. 1. Item 6 has four subparts (6.1-6.4) addressing motor 
and vocal phenomena associated with dreaming. Particularly 
pertinent to this study is item 6.3 with a question about 
SFOB within it: “I have or had the following phenomena dur-
ing my dreams: gestures, complex movements that are use-
less during sleep (e.g. to wave, to salute, to frighten mosqui-
toes), falls off the bed (yes/no)”.
23 All PD patients scored 
positively on item 10 concerning presence of CNS disease and 
this item was excluded from Fig. 1. The maximum score of 
the RBDSQ is 13 points. It was originally validated in 54 PSG-
confirmed RBD patients against control populations of sleep 
disorders patients and healthy sleepers.
23 Using a cut-off score 
of 5 as positive test for high risk for RBD, Stiasny-Kolster et 
al.
23 reported a sensitivity of 96% and specificity of 56% when 
compared with patients with a variety of sleep disorders. Our 
PD patients were categorized as high risk for RBD if they 
scored ≥5 on the RBDSQ.
SFOB
History of SFOB and related injury were assessed with the fol-
lowing two questions: 1) “Have you ever fallen out of bed dur-
ing sleep? If so, how many times have you fallen?” and 2) “Did 
you suffer any injuries from these falls? If so, what kind of in-
juries?”
RBD	clinical	mimickers
Screening questionnaires were used to detect for SDB and som-
nambulism, both of which have been associated with SFOB.
8,9 
The STOP questionnaire was utilized to identify high risk pa-
tients for SDB. This self-reported questionnaire asks four yes/
Fig. 1. Mean RBDSQ scores comparison. Data shown as mean 
±SD. p<0.01 for the comparison between the groups. RBDSQ: 
REM sleep behavior disorder screening questionnaire, SFOB: 
sleep-related falling out of bed.
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no questions about loud snoring, daytime tiredness, history of 
observed apneas, and history of hypertension or use of antihy-
pertensive medication.
25 Patients were classified as high risk 
for SDB if they endorsed positive responses on at least two of 
four questions. This questionnaire has been validated in preop-
erative clinics with surgical patients with sensitivities for de-
tecting mild, moderate, and severe obstructive sleep apnea of 
65.6, 74.3, and 79.5%, respectively.
25 One question assessing 
adult-onset somnambulism was also included. A semi-struc-
tured telephone interview for parasomnia history was per-
formed for those answering positively to this screening ques-
tion. Participants reporting SFOB were asked to complete 
prolonged one hour electroencephalography (EEG) to objec-
tively exclude underlying epileptic disorders. EEG was per-
formed in accordance with the International 10-20 system.
Data analyses
Demographics and clinical characteristics, RBDSQ responses, 
and RBD clinical mimickers questionnaire responses were 
compared for PD patients with and without SFOB.
Continuous variables are reported as means±(SD). The 
Mann-Whitney U test was used to compare nonparametric 
continuous and Chi-square or Fisher’s exact test were used to 
compare categorical variables. A modified Bonferroni correc-
tion was applied for multiple comparisons concerning the in-
dividual RBDSQ responses between the two groups.
26 Spear-
man’s rank correlation test was utilized to assess correlations 
between the RBDSQ total score and SFOB number, age of 
PD onset, age on questionnaire completion day, PD duration, 
H&Y stage and LEDD. Binary logistic regression analysis 
was performed to determine the clinical factors associated 
with prevalent SFOB. We entered all potential predictors of 
SFOB into a multiple logistic regression model without using 
backward or forward selection methods. We used the Hosmer-
Lemeshow goodness-of-fit statistic (p>0.05) to evaluate mod-
el fit.
For all analyses, p<0.05 was defined as statistically signifi-
cant. Statistical analyses were performed with SPSS Statistics 
17.0 (SPSS, Chicago, IL, USA).
Results
Demographics and clinical characteristics
The mean age of the 50 patients (34 men, 16 women) was 
68.0±11.6 years, and the mean age of PD onset was 59.4± 
12.8 years with a duration of 8.5±4.3 years and mean H&Y 
stage of 2.1±0.3. SFOB was present in 13 of the 50 patients. 
There were no significant differences between the SFOB and 
non-SFOB groups in gender distribution, mean age of PD on-
set, mean PD duration, mean H&Y stage, mean age at RBDSQ 
completion or mean education years (Table 1).
Visual hallucinations were more frequently reported in the 
SFOB group compared to the non-SFOB group. No differ-
Table 1. Demographic and clinical characteristics
All
(n=50)
SFOB
(n=13)
non-SFOB
(n=37)
Demographics
Age, years
PD onset, years
Sex (n, %)
Male
Female
PD duration, years
Hoehn-Yahr stage
Education, years
Depression or anxiety
Visual hallucinations*
Dyskinesias
Sleep-related injury*
  68±12
  59±13
34 (68)
16 (32)
  9±4
  2.2±0.4
15±3
11 (22)
  8 (16)
  6 (12)
  6 (12)
65±9
  56±11
10 (77)
  3 (23)
10±5
  2.3±0.3
14±4
  4 (31)
  5 (38)
  2 (15)
  5 (38)
  69±12
  61±13
24 (65)
13 (35)
  8±4
  2.1±0.3
15±3
  7 (19)
3 (8)
  4 (11)
1 (3)
Medications
LEDD (mg/day) 
Levodopa/Carbidopa
Entacapone
Dopamine agonist
Amantadine*
MAO inhibitors
Antidepressants
SSRIs
SNRIs
Bupropion
Quetiapine*
Cholinesterase inhibitors 
Anticholinergics
Benzodiazepines
  530±510
37 (74)
  7 (14)
22 (44)
16 (32)
23 (46)
  6 (12)
2 (4)
3 (6)
  6 (12)
  6 (12)
14 (28)
11 (22)  
  489±406
12 (92)
1 (8)
  5 (38)
  8 (62)
  9 (69)
1 (8)
1 (8)
  2 (15)
  5 (38)
  3 (23)
  4 (31)
  3 (23)
  545±546
25 (68)
  6 (16)
17 (46)
  8 (22)
14 (38)
  5 (14)
1 (3)
1 (3)
1 (3)
3 (8)
10 (27)
  8 (22)
Data shown as means±SDs or frequency (%), as appropriate.
*p<0.05. 
LEDD: levodopa equivalent daily dosage, MAO: monoamine 
oxidase, PD: Parkinson's disease, SFOB: sleep-related falling out 
of bed, SSRI: selective serotonin reuptake inhibitor.
Table 2. RBDSQ scores, high risk for RBD categorization and 
clinical mimickers
All
(n=50)
SFOB
(n=13)
non-SFOB
(n=37)
RBDSQ score*
†
High risk RBD diagnosis (n, %)*
RBD clinical mimickers (n, %)
High risk for SDB
Somnambulism
Questionnaires completed  
  by (n, %)
Patient alone
Patient and bed partner
4.6±3.0
22 (44)
16 (32)
3 (6)
29 (58)
21 (42)
8.3±3.0
12 (92)
  4 (33)
1 (8)
  6 (46)
  7 (54)
3.3±2.0
10 (27)
12 (34)
2 (6)
23 (62)
14 (38)
*p<0.01, 
†RBDSQ reported as mean±SD.
RBD: REM sleep behavior disorder, RBDSQ: REM sleep behavior 
disorder screening questionnaire, SDB: sleep disordered breath-
ing, SFOB: sleep-related falling out of bed.Sleep-Related Falling Out of Bed in PD
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ences between the groups were found regarding dyskinesias, 
depression or anxiety. None of the patients had a known his-
tory of seizure disorder. 
Sleep-related injury was reported on the questionnaires and 
medical record review by 12% of patients and was more fre-
quently reported in those with SFOB (Table 2). Overall, 13 
patients reported a history of at least one SFOB (26%) on the 
questionnaire but only 8 had mentioned SFOB on their clini-
cal visits; 5 (38%) patients reported only one episode, 3 pa-
tients (23%) reported two episodes and 5 (38%) patients re-
ported more than two episodes of SFOB. The episodes were 
sometimes separated by months or years. Injuries in the clini-
cal history and questionnaires included soft tissue trauma to 
neck, face, arms, and gluteus and one case of bitten tongue.
There was no significant difference between the SFOB and 
non-SFOB groups in their medications with the exception of 
higher use of amantadine and quetiapine in the SFOB group 
(Table 1). Two SFOB patients were prescribed amantadine 
for dyskinesias and six for anti-parkinsonian therapy. In the 
non-SFOB group, four patients used amantadine for dyskine-
sia and four more for anti-parkinsonian therapy. Of the 8 pa-
tients prescribed benzodiazepines, 5 (3 SFOB, 2 non-SFOB) 
were using clonazepam. All five SFOB patients with halluci-
nations were treated with quetiapine. None of the patients re-
ported onset of SFOB within one month of introduction of 
antidepressant medication.
Questionnaires
The mean RBDSQ score was significantly higher in the SFOB 
group (8.3±3.0 vs. 3.3±2.0)(Fig. 1). Individual item response 
differences between the groups are shown in Fig. 2. The ques-
tionnaires were completed either by the patient alone (58%), 
or by the patient and bed partner (42%). Patients who com-
pleted the RBDSQ with their bed partner had a significantly 
higher score compared with those completing it alone (5.3±2.6 
vs. 4.0±3.4, p=0.033); however, there was no significant dif-
ference in bed partner participation in completion of question-
naires in either group (Table 2).
High risk for RBD categorization
Forty-four percent of patients fulfilled high risk for RBD cri-
teria, 55% of whom reported SFOB (Table 2). Eight high risk 
for RBD patients (4 SFOB, 4 non-SFOB) were also high risk 
for SDB.
RBD clinical mimickers
There was no difference in the prevalence of patients who were 
at high risk for SDB or who reported somnambulism between 
the two groups. One high risk for RBD patient with SFOB re-
ported multiple episodes of adult-onset somnambulism unre-
lated to medication use or snoring. Out of the non-SFOB pa-
tients with active history of somnambulism, one was high risk 
for OSA and the second patient’s episodes were associated 
with zolpidem use. Three patients (1 SFOB, 2 non-SFOB) did 
not complete this questionnaire and were excluded from the 
statistical analysis.
Ten SFOB subjects (77%) completed one hour EEG, each 
including at least 10 minutes of sleep. Seven subjects had un-
remarkable EEG results, while the remaining 3 subjects had 
either intermittent left (1 subject) or right (2 subjects) tempo-
ral slowing. None of the subjects had finding suggestive of 
underlying seizure disorder (i.e. epileptiform activity or spike 
and wave pattern).
Correlation tests showed that the RBDSQ score is mildly 
associated with PD duration (rs=0.31, p=0.025), H&Y stage 
(rs=0.37, p=0.008) and LEDD (rs=0.32, p=0.024) but not with 
SFOB number (rs=0.14, p=0.32), age of PD onset (rs=-0.001, 
p=0.99) or the age at RBDSQ completion (rs=0.081, p=0.57).
Logistic regression analysis was performed to identify clin-
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Fig. 2. Individual RBDSQ item prevalence of SFOB (grey) and 
non-SFOB group (black). RBDSQ: REM sleep behavior disorder 
screening questionnaire, SFOB: sleep-related falling out of bed. 
*p<0.05, **p<0.01.
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ical characteristics associated with SFOB in PD patients. 
Prevalent SFOB was the dependent variable and age, gender, 
PD duration, high risk for SDB, and RBDSQ score included 
as the independent variables. Goodness-of-fit testing revealed 
that the model accounted for the outcome better than chance 
alone (p<0.001) and that the predicted likelihood of the out-
come was similar to the observed likelihood (p=0.24). The 
model performance was good with 67% of the variance in the 
outcome explained by the model. The overall accuracy of this 
model to predict subjects with prevalent SFOB (with a pre-
dicted probability of 0.5 or greater) is 94%. The sensitivity is 
75% and the specificity is 100%. Positive predictive value is 
100% and negative predictive value is 92%.
For every one unit increase in RBDSQ score the likelihood 
of SFOB increased by 2.4 (OR 2.4, 95% CI 1.3- 4.2, p<0.003). 
For every one unit increase in age, the likelihood of SFOB 
decreased by 6%. The latter, however, was not statistically sig-
nificant. Similarly duration of PD, gender and risk for SDB 
did not have a statistically significant association with SFOB 
in our model.
Discussion
Prevalence of SFOB
This is the first study that focuses in detail on SFOB as a dis-
tinct clinical event in PD. SFOB was relatively common, re-
ported by 26% of participants and significantly associated 
with sleep-related injury. Scaglione et al.
4 found similar rates 
of “attempts to get out of bed,” with 24% of PD patients with 
clinically-defined RBD reporting it occurred “sometimes”; 
however, it is unclear if these “attempts to get out of bed” are 
equivalent to SFOB. In a heterogenous sample, Lin et al.
6 re-
ported that 27% of Chinese patients with idiopathic and symp-
tomatic PSG-verified RBD (including 11 with PD) had “acci-
dental falling from the bed” In contrast, Iranzo et al.
3 reported 
higher rates of falling out of bed (38.5%) in PD patients with 
PSG-verified RBD.
PD is predominantly a disease of older patients with its prev-
alence increasing with age.
27 Epidemiological studies estimate 
RBD prevalence to be 0.5% in older populations,
15 while sleep-
related injury has been estimated to occur in 0.8% of the elder-
ly.
7 Falls in the elderly can have serious consequences includ-
ing vertebral and hip fractures, head trauma or even fatal 
injuries.
28 Even minor injuries have the potential to further 
hamper mobility in PD patients. Overall, 12% of our PD pa-
tients reported sleep-related injury, approximately one-third of 
those with SFOB. This injury rate is consistent with that re-
ported by Lin et al.
6 (39%) who employed a retrospective de-
sign without bed partner involvement. Other investigations 
with higher rates of bed partner involvement have reported 
higher sleep-related injury rates associated with RBD in PD, 
recognizing that falling out of bed is a high risk event.
4,5,10 The 
lower sleep-related injury rate reported may partially be ex-
plained by the injury assessment methods, limited to injuries 
resulting exclusively from sleep-related falls and not to other 
potentially dangerous manifestations of RBD (ie punching).
Patient characteristics
PD patients with SFOB were similar to those without SFOB 
in demographic, clinical characteristics and medication regi-
men except for the higher presence of visual hallucinations 
and the more common use of amantadine and quetiapine. In 
contrast to the older age, longer PD duration, higher H&Y 
stage, and male predominance noted in some of the larger 
studies of RBD in PD,
4,14,20,29 we did not find these clinical 
variables were more common in patients reporting SFOB. 
Amantadine treatment was more common in the SFOB group 
compared to the non-SFOB group given its higher use as anti-
parkinsonian therapy. Visual hallucinations were more com-
mon in the SFOB group, explaining the higher use of quetiap-
ine. The 5 patients with visual hallucinations were significantly 
older compared to the rest of the SFOB sample, and had mul-
tiple medical co-morbidities including depression, known risk 
factors for hallucinations in PD.
30 It is possible that nocturnal 
hallucinations in the sleep-wake transition may have contrib-
uted to SFOB.
RBDSQ scores
Our study is one of the first to report on the range of RBDSQ 
scores in a PD population. Only two of the RBD patients in 
the original RBDSQ study had PD, and therefore, the useful-
ness of the RBDSQ in PD is currently unknown. Our patients 
with SFOB had significantly higher total mean RBDSQ scores 
than those without SFOB (Table 2). There was no difference 
in the distribution of patients with somnambulism or at high 
risk for SDB between the SFOB and non-SFOB groups, sug-
gesting that overrepresentation of these clinical mimickers 
did not account for differences in RBDSQ scores.
We found a correlation between the RBDSQ score, PD du-
ration, H&Y stage and LEDD. These three clinical variables 
represent markers of advanced PD. Longer PD duration and 
motor disability has been associated with RBD in PD, sugges-
tive of more widespread brainstem pathology underlying REM 
sleep without atonia.
4,10,29 The lack of correlation between 
RBDSQ score and SFOB number may be related to recall bias 
as most patients reported SFOB occurring in recent years. Al-
though it has been shown to detect even mild manifestations 
of RBD, it is doubtful that the RBDSQ could be utilized to de-
tect “severity” of RBD in PD as it does not include frequency 
of nocturnal behaviors. Li et al.
31 recently-published a new Sleep-Related Falling Out of Bed in PD
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RBD screening questionnaire (RBD-HK) which weighs life-
time occurrences of abnormal nocturnal behaviors and their 
frequency over the last year, providing a score for measuring 
RBD severity and tracking changes over time. Future studies 
should address the utility of these screening questionnaires to 
risk-stratify patients for initial or recurrent SFOB.
Our modeling was able to explain much of the variance in 
the dependent variable with good diagnostic performance. It 
highlights the importance of the RBDSQ score in predicting 
the odds of SFOB in patients with PD, with patients with 
higher scores (and thus increased probability of RBD) being 
more likely to fall out of bed.
High risk for RBD categorization and clinical 
mimickers
Overall, 44% of our participants screened high risk for RBD, 
a rate consistent with those reported in PD populations using 
clinical RBD criteria.
4,10,14,29 SDB may have co-existed with 
RBD in 8 patients, a finding noted in the literature.
10,11 In these 
patients, it is possible that RBD phenomena may have been 
triggered by REM sleep-related respiratory events. In our 
model, we did not find an association between increased risk 
for SDB and SFOB. Although three subjects had intermittent 
temporal slowing on extended one hour EEG, this finding has 
been noted in about 10% of elderly patients and is of unclear 
clinical significance.
32 None of the SFOB patients completing 
1 hour of EEG (10 patients) had definitive evidence sugges-
tive of latent seizure disorder making the possibility that 
SFOB was an ictal phenomenon less likely.
Study limitations
Our study has several limitations, the most important of which 
is the absence of PSG to verify the clinical suspicion of RBD. 
A recent small case series from our group showed that in the 
majority of PD patients reporting SFOB (5 of 6), PSG con-
firmed suspected RBD diagnosis.
33 The categorization of high 
risk for RBD was based on a discriminative score of 5 on the 
RBDSQ, a score which has not been validated in a PD popu-
lation; however, other investigations have used this cut-off 
score in PD patients to determine RBD status.
34 Unfortunate-
ly, we were unable to definitively diagnose RBD as many of 
the patients refused PSG due to cost or distance to our medical 
center. Since 2005, the International Classification of Sleep 
Disorders Coding and Diagnostic Manual 2
nd edition requires 
PSG as part of RBD diagnostic criteria to exclude clinical 
mimickers of RBD and verify loss of normal skeletal muscle 
atonia during REM sleep.
35 The prevalence of RBD in idio-
pathic PD assessed by clinical interviews alone varies be-
tween 15-46% and is increased to 46-58% when performed in 
conjuction with PSG.
3 Hence, questionnaire assessment alone 
is insufficient to diagnose RBD. Our high risk for RBD cate-
gorization is only suggestive and not diagnostic of RBD. We 
tried to objectively exclude nocturnal seizure phenomena by 
asking SFOB patients to complete daytime EEG. Unfortunate-
ly, all subjects could not undergo EEG due to absence of clin-
ical indications. Although we tried to control for temporal as-
sociation of medications known to influence RBD in the 
clinical history,
36,37 it is possible that medications impacted 
SFOB occurrence or its absence; however, there was no sig-
nificant differences in the use of these medication between the 
two groups. The majority of patients completed the question-
naires alone, likely underestimating the true prevalence of 
sleep-related complaints/RBD phenomena. Bed partner in-
volvement will improve answers to some items on the RBDSQ 
as reflected by the significantly higher RBDSQ scores in those 
completing it with bed partners. Due to our small sample size, 
we could only control for a limited number of variables in our 
logistic regression analysis and we cannot exclude modest dif-
ferences between groups.
The focus on SFOB is important as it is a potentially dan-
gerous clinical but easily recognizable event. The natural his-
tory of SFOB in PD patients is currently unknown as are risk 
factors for future SFOB. Although we cannot equate SFOB 
with RBD in PD, when clinical events are highly suggestive 
of RBD, PSG confirms REM sleep without atonia in the large 
majority of cases. In our cohort, the majority of patients re-
porting fall-related injury had a history of SFOB before suf-
fering injury, presenting a window of opportunity for inter-
vention. Patients who may experience SFOB may not injure 
themselves and therefore, not report it to their healthcare pro-
vider. Asking about SFOB may be useful in busy movement 
disorders clinics to identify high-risk patients who merit ex-
peditious sleep evaluation and immediate conservative treat-
ment. Although patients reporting SFOB may represent only 
a fraction of PD patients with RBD, they may be a large pro-
portion of those who require pharmacologic treatment to pre-
vent imminent injury. Future prospective studies are needed 
to assess SFOB etiology in PD with PSG, define its natural 
evolution, risk factors for recurrent SFOB, and characterize its 
treatment response. 
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